A Clinical Phase I/II, Multicenter, Open-label, National Study Evaluating Quintuplet Treat-ment With ISaTuximab, Bortezomib, Lenalidomide and Dexamethasone Plus Etentamig (Etenta-Isa-VRd) in Primary DiagnOsed High-Risk Multiple Myeloma Patients

This study is researching an experimental five-drug combination called etentamig, isatuximab, bortezomib, lenalidomide, and dexamethasone. The study is focused on participants with newly diagnosed multiple myeloma (NDMM) and high-risk disease who are eligible for autologous stem cell transplantation.

Start Date01 Dec 2026

Sponsor / Collaborator

Universitätsklinikum Hamburg-Eppendorf

[+2]

NCT07247097

/ Not yet recruitingPhase 2IIT

ELDORADO: a Randomized Phase II Trial of Elranatamab or Daratumumab in Combination With Lenalidomide, Bortezomib, and Dexamethasone (RVd Lite) in Newly Diagnosed, Transplant Ineligible/Deferred Multiple Myeloma

This research study is being done to compare the efficacy and safety of the combination of elranatamab, lenalidomide, bortezomib, dexamethasone versus the combination of daratumumab, lenalidomide, bortezomib, dexamethasone for patients with newly diagnosed, transplant ineligible/deferred multiple myeloma.

Start Date01 Aug 2026

Sponsor / Collaborator

The Massachusetts General Hospital

[+1]

NCT07341867

/ Not yet recruitingPhase 1IIT

A Pilot Study of Duffy Null-Specific Dose Modifications for Individuals With Duffy Null Phenotype Receiving Standard of Care Systemic Anti-Cancer Therapies

This study is comprised of a main study, an observational study, and optional survey studies. The main study is being done to see whether using Duffy null specific treatment dosing guidelines can reduce or delay dose modifications and avoid neutropenic fever (fever in the setting of low neutrophils) for people with Duffy null phenotype receiving treatment for multiple myeloma or triple negative breast cancer. The observational study is to collect dose modification and neutropenic fever information on patients who do not have the Duffy null phenotype and receive the same standard of care regimens to see if there are differences in dose modifications and neutropenic fever between the two groups. The survey studies seek to understand general health experiences and preferences and experiences specific to people with Duffy null phenotype.
Study Drugs Include:
* Daratumumab
* lenalidomide
* bortezomib
* dexamethasone
* carboplatin
* paclitaxel
* pembrolizumab
* cyclophosphamide
* doxorubicin

Start Date01 Aug 2026

Sponsor / Collaborator

Dana-Farber Cancer Institute, Inc.

100 Clinical Results associated with Lenalidomide

100 Translational Medicine associated with Lenalidomide

100 Patents (Medical) associated with Lenalidomide

7,643

Literatures (Medical) associated with Lenalidomide

31 Dec 2026·Hematology

Secondary poor graft function after autologous stem cell transplantation in multiple myeloma: a case-based expert review and successful rescue with secondary autologous stem cell infusion

Review

Author: Song, Xiaoning ; Liu, Xiaojun ; Suo, Jing ; Lu, Jiapei ; Meng, Yuan ; Meng, Jianbo ; Zhang, Jinqiao ; You, Jiawen ; Zhang, Yuanyuan ; Dai, Yuxin ; Zang, Meirong

INTRODUCTION:

Secondary poor graft function (PGF) after autologous hematopoietic stem cell transplantation (Auto-HSCT) for multiple myeloma (MM) is rare, often delayed in recognition, and lacks standardized salvage algorithms.

AREAS COVERED:

Using a case-based expert-review format, we summarize diagnostic hallmarks, exclusion work-up, mechanistic drivers, and practical management, with emphasis on autologous stem-cell boost as a rescue option.

CASE SUMMARY:

A 59-year-old woman with IgG κ MM achieved timely neutrophil and platelet engraftment after Auto-HSCT, then developed recurrent transfusion-dependent pancytopenia approximately two months later. Relapse, occult infection/viral reactivation, immune cytopenia, nutritional deficiency, and drug-related myelosuppression were systematically excluded, supporting secondary PGF. Growth factors and thrombopoietin-receptor agonists produced only transient benefit. A second infusion of cryopreserved autologous peripheral blood stem cells (PBSCs) (3.621 × 10⁶ CD34⁺/kg) without re-conditioning led to rapid platelet recovery within 7 days and durable trilineage hematopoiesis.

EXPERT OPINION:

Secondary PGF after Auto-HSCT appears multifactorial, involving quantitatively adequate but qualitatively fragile grafts, inflammatory/microenvironmental injury, and therapy-related megakaryocytic vulnerability (including heavy lenalidomide exposure). When backup cells are available and reversible causes are excluded, early unpreconditioned autologous PBSC boost is a safe, feasible, and likely under-utilized salvage strategy. Strategic PBSC banking and early recognition may prevent life-threatening PGF.

31 Dec 2026·JOURNAL OF MEDICAL ECONOMICS

Indirect treatment comparison of DVRd plus DR maintenance (PERSEUS study) versus DVTd or VTd with or without lenalidomide maintenance in transplant-eligible patients with previously untreated multiple myeloma

Article

Author: Einsele, Hermann ; Facon, Thierry ; Nair, Sandhya ; Dimopoulos, Meletios A. ; He, Jianming ; Caillot, Denis ; Sonneveld, Pieter ; Zweegman, Sonja ; Ammann, Eric ; Spencer, Andrew ; Nobrega, Marjorie ; Broijl, Annemiek ; Perrot, Aurore ; Schjesvold, Fredrik ; Gay, Francesca ; Boccadoro, Mario ; Hajek, Roman ; Rodriguez-Otero, Paula ; Hulin, Cyrille ; Sitthi-Amorn, Anna ; Rowe, Melissa ; Leleu, Xavier ; Mina, Roberto

AIMS:

To compare the effectiveness of induction and consolidation with daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd) plus maintenance therapy with daratumumab and lenalidomide (DR) with 2 treatment regimens that are widely used for transplant-eligible newly diagnosed multiple myeloma (TE NDMM): bortezomib, thalidomide, and dexamethasone (VTd) or daratumumab-VTd (DVTd) followed by observation (Obs) or lenalidomide maintenance.

MATERIALS AND METHODS:

Individual patient-level data from the PERSEUS (NCT03710603) and CASSIOPEIA (NCT02541383) trials were used to compare DVRd + DR with VTd + Obs and with DVTd + Obs. Inverse probability of treatment weighting was used to adjust for differences in baseline patient characteristics between the two trials; inverse probability of censoring weighting was used to adjust for the second randomization of CASSIOPEIA. Data from the CASSIOPEIA and Myeloma XI (EudraCT 2009-010956-93) trials were combined to model outcomes associated with lenalidomide (R) maintenance following induction with DVTd or VTd.

RESULTS:

DVRd + DR showed superior progression-free survival compared with DVTd + Obs (hazard ratio, 0.39 [95% CI = 0.26-0.59]), VTd + Obs (0.17 [95% CI = 0.12-0.25]), DVTd + R (0.62 [95% CI = 0.41-0.92]), and VTd + R (0.29 [95% CI = 0.18-0.43]). Sensitivity analyses showed results were consistent with the base case.

LIMITATIONS:

The indirect treatment comparison was unanchored due to a lack of common comparators and relied on external data from the Myeloma XI trial to model outcomes associated with DVTd or VTd followed by R maintenance. Despite best efforts to identify and adjust for important treatment effect modifiers, there is a potential for residual confounding.

CONCLUSIONS:

Findings from this study suggest that DVRd followed by DR maintenance offers superior survival outcomes compared with current standards of care in TE patients with NDMM.

31 Dec 2026·Hematology

Neutrophil extracellular trap-related genes in PTCL: identification, prognosis and drug interaction prediction via bioinformatics-machine learning

Article

Author: Chen, Jing ; Cheng, Fanjun ; Fang, Jun

OBJECTIVE:

This study aimed to identify neutrophil extracellular trap-related genes (NET-RGs), explore their prognostic significance, and predict drug interactions in peripheral T-cell lymphoma (PTCL).

METHODS:

Differentially expressed NET-RGs (DE-NRGs) between PTCL and normal tissues were screened. Functional enrichment analysis was conducted. Bioinformatics and machine learning were used to identify hub genes and assess their diagnostic value. Univariate and multivariate analyses were used to evaluate prognostic roles. Correlation and immune infiltration analyses were performed to explore relationships with the tumor microenvironment (TME). Clinical data were collected from PTCL patients who received potential agents (lenalidomide) as first-line treatment.

RESULTS:

A total of 31 DE-NRGs were identified (18 upregulated and 13 downregulated), enriched in inflammatory response, extracellular matrix organization, and infection involvement. Four hub genes (AKT2, MAPK14, IRF1, and TNF) were identified as effective PTCL diagnostic markers. Higher AKT2/MAPK14 expression correlated with poorer overall survival (OS), while elevated TNF expression associated with better OS; AKT2 and TNF independently predicted OS. These genes were implicated in modulating TME remodeling. Potential therapeutic agents (e.g. capivasertib, lenalidomide) were predicted, and lenalidomide may represent a feasible initial treatment option for PTCL, with an objective response rate (ORR) of 40.0% and a maximum survival duration exceeding 50 months.

CONCLUSION:

NET-RGs play crucial roles in diagnosis, prognosis, and TME regulation, and lenalidomide, a putative TNF-targeting agent, may represent a feasible initial treatment option in PTCL.

1,187

News (Medical) associated with Lenalidomide

21 Jul 2026

·www.biospace.com

Enterome Phase 2 data show EO2463-induced CD8 T-cell expansion correlates with progression-free survival in patients with indolent non-Hodgkin lymphoma in the watch-and-wait setting

PRESS RELEASE Magnitude of EO2463-induced CD8 T-cell expansion during monotherapy statistically significantly associated with longer progression-free survival (PFS) in patients with indolent non-Hodgkin lymphoma (iNHL) managed in the watch-and-wait setting EO2463-induced CD8 T-cell expansion also statistically significantly associated with complete response rate in patients with relapsed/refractory iNHL treated with EO2463 in combination with lenalidomide and rituximab (R²) Findings support EO2463-induced CD8 T-cell expansion as a potential predictive biomarker for clinical benefit Data presented at Pan Pacific Lymphoma Conference (PPLC) Enterome will also present data on its solid-tumor OncoMimics™ candidate EO4010 at the European Society for Medical Oncology (ESMO) Congress 2026 Paris, France – 21 July 2026 Enterome SA , a clinical-stage company pioneering OncoMimics™, a new class of off-the-shelf, multi-targeted in vivo immune therapies , today announced new positive interim data from the ongoing open-label Phase 1/2 SIDNEY trial of OncoMimics™ EO2463 to treat indolent Non-Hodgkin Lymphoma (iNHL). The data show EO2463 continues to have an effect, now showing a statistically significant correlation with progression-free survival (PFS) as a monotherapy in the watch-and-wait setting, and an additive effect, associated with complete response rates, when used in a triple combination, together with the standard of care, lenalidomide and rituximab (R 2 ). These new findings confirm previous data suggesting specific CD8 T cell expansion caused by EO2463 could be developed as a predictive biomarker and represent a compelling rationale for further study to confirm that EO2463 increases PFS in patients with iNHL. ezstandalone.cmd.push(function () { ezstandalone.showAds(131); }); Enterome presented the data today at the Pan Pacific Lymphoma Conference (PPLC) at the Fairmont Orchid, Kohala Coast (Big Island) in Hawaii. Copy of the poster is available here . “The correlation between the robust CD8 T cell expansion induced by EO2463 and PFS is a landmark finding that creates an imperative for further study and offers new hope for patients suffering from iNHL. It suggests that EO2463, which has been well-tolerated to date, may effectively extend PFS as a standalone therapy without hurting quality of life in this generally older and fragile patient population. We want to prioritize patients classified for watch-and-wait, an observational protocol, because they currently receive no active treatment, despite having to live with the grave psychological impact of their cancer diagnosis,” said Pierre Belichard, Chief Executive Officer of Enterome. “Based on these and other data, we believe EO2463 is ready to start the final stage of registrational clinical development as a first-in-class therapeutic for patients with iNHL in a watch-and-wait setting. We are in active discussions with potential investors and partners to find the best way to bring this product to patients.” SIDNEY (NCT04669171) is an ongoing open-label Phase 1/2 study evaluating the safety, tolerability, immunogenicity and preliminary efficacy of EO2463 as monotherapy and in combination regimens patients with follicular lymphoma and marginal zone lymphoma. The trial includes a dedicated watch-and-wait monotherapy cohort, a first-line low-tumor-burden combination cohort with rituximab, and relapsed/refractory cohorts treated with EO2463+R 2 . Interim data continue to support further evaluation of EO2463 both as a standalone treatment and in combination with established anti-lymphoma therapies. More recently, as SIDNEY progresses, data have begun to show the impact of EO2463 on clinical efficacy. Enterome reported at ASH in late 2025 that EO2463 caused a higher-than-expected complete recovery (CR) rate with the triple combination therapy, EO2463 and R2, compared to the combination of only lenalidomide and rituximab (or “R2”). Data reported at ASH in late 2024 showed that EO2463 monotherapy generated a 46% objective response rate in watch-and-wait patients. Last month, at EHA 2026 , Enterome presented data showing that EO2463-induced CD8 T cell expansions were significantly associated with clinical outcomes in each of the monotherapy, rituximab (“R1”), and R2 cohorts, suggesting that EO2463-induced CD8 T-cell expansion can be used as a predictive biomarker. Today, Enterome announced that new analyses extend this finding to progression-free survival in the monotherapy cohort. Key data presented at PPLC: In the EO2463 monotherapy cohort (Cohort 2, watch-and-wait), higher CD8 T cell expansion was significantly associated with longer progression-free survival (HR=0.18, 95% CI 0.03–0.82; log-rank p=0.020). In the EO2463 plus lenalidomide/rituximab combination cohort (Cohort 1+4, relapsed/refractory disease), higher CD8 T cell expansion was significantly associated with complete response (p=0.0073) EO2463 is an off-the-shelf OncoMimics™ active immunotherapy composed of four synthetic microbial-derived peptides designed to mimic the B-cell lineage markers CD20, CD22, CD37 and CD268 (BAFF receptor), plus the helper peptide UCP2. This multi-target approach is intended to expand pre-existing memory CD8 T cells, selectively target malignant B cells, broaden target coverage and obviate antigen escape. In May 2026, the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to EO2463 for treatment of patients with follicular lymphoma . Upcoming presentation at ESMO Congress 2026 Enterome will also present data on its solid-tumor OncoMimics™ candidate EO4010 at the European Society for Medical Oncology (ESMO) Congress 2026 , taking place 23–27 October 2026 in Madrid, Spain. Title : EO4010 (EO) multi-target peptide immunotherapy: tumor directed CD8 T cell expansion kinetics and association to survival in patients (pts) with treated mismatch repair proficient (pMMR) metastatic colorectal carcinoma (mCRC) Presentation number : 859P Presentation time : Sun, October 25, 2026 – Time: 12:00 - 12:45 OncoMimics™  consist of bacteria-derived peptide antigens that closely mimic tumor-associated antigens (TAAs) of solid tumors, or lineage markers (e.g. as observed in B cell lymphomas). These peptides induce a fast and potent  in vivo  expansion of effector-memory CD8 T-cells, naturally primed by gut bacteria, and cross-reactive with TAAs/B cell markers, thereby eliciting cytotoxic responses against tumor cells. Because they are recognized as foreign entities by the immune system, OncoMimics™ help overcome the self-tolerance that limits the ability of many cancer immunotherapies to trigger rapid, potent, and durable endogenous immune responses. The synthetically produced OncoMimics™ peptides are selected and designed  in silico  by mining Enterome’s proprietary database of 23 million commensal bacteria genes. Each product combines multiple highly immunogenic peptides specifically designed to broaden target coverage, mitigate tumor heterogeneity and obviate the cancer’s ability to escape the therapeutic intervention. Enterome SA ( ) is a privately held clinical-stage biopharmaceutical company developing breakthrough OncoMimics™ immunotherapeutics for cancer. The three most advanced product candidates have shown positive early data in Phase 2 clinical development, supporting the novel OncoMimics™ modality. The company’s pioneering approach to drug discovery is based on the unique and powerful bacterial Mimicry drug discovery platform, which allows it to discover OncoMimics™ with high similarity to tumor associated antigens (TAA) based on the big-data insights from millions of gut bacterial proteins that live in humans. For more information, please contact: ENTEROME Pierre Belichard Chief Executive Officer communication@enterome.com INVESTOR & MEDIA RELATIONS Chris Maggos / Giovanni Ca’ Zorzi +41 (0)79 367 6254 / +33 (0)7 84 67 07 27 enterome@cohesionbureau.com Attachment 20260721 Enterome PR PPLC_FINAL

ImmunotherapyClinical ResultOrphan DrugPhase 2Cell Therapy

16 Jul 2026

·www.biospace.com

Landmark ECOG-ACRIN ENDURANCE Study Co-Authored by International Myeloma Foundation Leaders Provides Evidence for Optimal Duration of Maintenance Therapy

STUDIO CITY, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Study results from the randomized, prospective phase III ENDURANCE (E1A11) trial, designed and conducted by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN), were published today in the New England Journal of Medicine. The study was co-authored by several members of the International Myeloma Foundation (IMF) leadership who also serve on the ECOG-ACRIN Myeloma Committee, which led the study. These investigators include Dr. S. Vincent Rajkumar, Chairperson of the IMF Board of Directors (Mayo Clinic — Rochester, MN); Dr. Shaji Kumar, Member of the IMF Scientific Advisory Board (Mayo Clinic — Rochester, MN); and Dr. Sagar Lonial, Vice Chairperson of the IMF Board of Directors (Winship Cancer Institute, Emory University — Atlanta, GA). The phase III ENDURANCE trial results showed that two years of maintenance therapy with lenalidomide provides the same long-term survival benefit as indefinite treatment until progression for patients with standard-risk multiple myeloma. ezstandalone.cmd.push(function () { ezstandalone.showAds(131); }); The trial enrolled 516 patients who have completed initial treatment but were not candidates for upfront stem cell transplantation. Participants were randomly assigned to receive lenalidomide either until progression, which is the current standard of care (indefinite duration group) or for a limited duration of 2 years. After nearly seven years of follow-up, overall survival rates were virtually identical: 68.6 percent in the indefinite treatment group versus 69.0 percent in the two-year limited duration group. Compared to the limited duration group, indefinite duration of therapy was associated with higher rates of side effects, including fatigue, anemia, and diarrhea. The study also found a slightly higher incidence of second primary cancers over five years among patients who took the drug until progression. “For years, patients and clinicians have been hesitant to stop lenalidomide maintenance because we didn’t know how long was required for optimal benefit,” said lead author Dr. Shaji Kumar, co-chair of the ECOG-ACRIN Myeloma Committee. “Our trial results show that two years is sufficient and that continuing the drug longer adds toxicity without extending life.” Dr. S. Vincent Rajkumar, senior author and chair of the ECOG-ACRIN Myeloma Committee, said: “Our findings suggest that a fixed-duration approach can become the new standard of care, at least for standard-risk patients, allowing us to pause treatment, monitor patients closely, with the option of potentially re-introducing lenalidomide or other new active treatments if the disease returns.” According to co-author Dr. Sagar Lonial, “this is the first randomized trial to show that limited duration lenalidomide maintenance does not sacrifice overall survival in the context of no transplant and triplet induction.” “The impact of these study results on patients cannot be overstated from a quality-of-life perspective,” said Heather Cooper Ortner, IMF President and CEO. “For patients with standard-risk myeloma, knowing with confidence that they can safely discontinue treatment without compromising overall survival represents a remarkable advancement in personalized care. It means fewer side effects, less time on therapy, and greater freedom to focus on living their lives—not just managing their disease. This is exactly the kind of research that gives patients hope while bringing us closer to our ultimate goal: helping every patient live longer, better lives until we achieve a cure.” Multiple myeloma, a cancer of plasma cells, has seen dramatic advances in treatment over the past two decades. However, prolonged therapy has raised concerns about cumulative side effects and financial burden. This trial addresses a critical gap by proving that shorter, fixed-duration maintenance may not compromise efficacy. The results are particularly relevant for patients without high-risk cytogenetic risk factors and those who did not undergo stem cell transplantation, representing a large portion of the myeloma population. The study was funded by the US National Institutes of Health, National Cancer Institute. Additional support was provided by Amgen. ClinicalTrials.gov identifier: NCT01863550. ABOUT MULTIPLE MYELOMA Multiple myeloma is a cancer of the bone marrow plasma cells — white blood cells that make antibodies. A cancerous or malignant plasma cell is called a myeloma cell. Myeloma is called “multiple” because there are frequently multiple patches or areas in bone where it grows. It often involves damage to bone and kidneys. Multiple myeloma is still incurable, but great progress has been made in terms of survival over the last two decades. The disease is twice as common and is diagnosed at a younger age in African Americans than white Americans. The most common presenting symptoms include fatigue and bone pain. ABOUT THE INTERNATIONAL MYELOMA FOUNDATION Founded in 1990, the International Myeloma Foundation (IMF) is the world’s leading organization dedicated to multiple myeloma. The IMF is steadfast in its mission: accelerating the prevention and cure of myeloma and improving the quality of life for patients and families. The IMF serves people impacted by myeloma at every stage of the disease by combining world-class research, trusted education, global advocacy, and direct support. A cornerstone of this work is the International Myeloma Working Group ® (IMWG)—a network of more than 380 internationally renowned researchers and clinicians who establish the guidelines that shape how myeloma is diagnosed, treated, and managed across the globe. Through its global network of support groups, educational programs, its 24/7 generative-AI myeloma assistant Myelo ® , its InfoLine, and its advocacy for greater healthcare access, the IMF helps people living with myeloma and their care partners navigate diagnosis, treatment, and survivorship. At the same time, the IMF ensures scientific advances translate into better care and outcomes.   Learn more at  or contact the IMF InfoLine at (800) 452-CURE (2873) (U.S. & Canada), +1 (818) 487-7455 (worldwide), or  infoline@myeloma.org . Follow the IMF on: X/Twitter:  @IMFmyeloma Instagram:  @imfmyeloma Facebook:  @myeloma LinkedIn:  International Myeloma Foundation Bluesky:  @imfmyeloma.bsky.social Media Contacts:   Peter Anton   Panton@myeloma.org Jason London   Jlondon@myeloma.org

15 Jul 2026

·pmlive.com

Bristol Myers Squibb’s New Drug Application for mezigdomide accepted by FDA

Bristol Myers Squibb’s New Drug Application (NDA) for mezigdomide has been accepted by the US FDA. Mezigdomide is an oral cereblon E3 ligase modulator, or CELMoD, that leads to higher multiple myeloma cell killing and immune stimulation than traditional immunomodulatory agents. The application is based on results from the phase 3 SUCCESSOR-2 trial showing oral CELMoD mezigdomide, in combination with carfilzomib and dexamethasone (MeziKd), significantly improves progression-free survival in patients with relapsed or refractory multiple myeloma (RRMM) vs standard of care. The phase 3 trial of MeziKd showed a 52% reduction in the risk of disease progression or death compared with Kd in patients with RRMM, including those at first relapse after prior treatment with an anti-CD38 monoclonal antibody and lenalidomide. Pre-clinical data suggests the drug enhances T-cell function and reinvigorates patients’ exhausted immune systems. It is also being evaluated in the ongoing phase 3 SUCCESSOR-1 trial vs. standard of care regimen in relapsed or refractory multiple myeloma. “The FDA’s acceptance of our application for mezigdomide highlights the continued momentum of our targeted protein degradation programmes, as we now have two distinct agents under review in relapsed or refractory multiple myeloma, which remains a persistent disease,” said Cristian Massacesi, executive vice president, chief medical officer and head of development, Bristol Myers Squibb. “We’re rapidly progressing the development of our CELMoD pipeline and are committed to leveraging this platform to bring the next wave of advances for patients in both hematologic malignancies and solid tumours.” Results were recently presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting as a late-breaking oral presentation and published in The Lancet. The US FDA has assigned a target action date of 13 May 2027 for this New Drug Application.

Phase 3Clinical ResultASCONDA

100 Deals associated with Lenalidomide

External Link

KEGG	Wiki	ATC	Drug Bank
D04687	Lenalidomide	L04AX04	DB00480

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Large B-cell lymphoma	United States	Seagen, Inc.	11 Feb 2025
Marginal Zone B-Cell Lymphoma	United States	Bristol Myers Squibb Co.	28 May 2019
Adult T-Cell Leukemia-Lymphoma	Japan	Bristol-Myers Squibb KK	02 Mar 2017
Chromosome 5q Deletion Syndrome	European Union	Bristol-Myers Squibb Pharma EEIG	14 Jun 2007
Chromosome 5q Deletion Syndrome	Iceland	Bristol-Myers Squibb Pharma EEIG	14 Jun 2007
Chromosome 5q Deletion Syndrome	Liechtenstein	Bristol-Myers Squibb Pharma EEIG	14 Jun 2007
Chromosome 5q Deletion Syndrome	Norway	Bristol-Myers Squibb Pharma EEIG	14 Jun 2007
Follicular Lymphoma	European Union	Bristol-Myers Squibb Pharma EEIG	14 Jun 2007
Follicular Lymphoma	Iceland	Bristol-Myers Squibb Pharma EEIG	14 Jun 2007
Follicular Lymphoma	Liechtenstein	Bristol-Myers Squibb Pharma EEIG	14 Jun 2007
Follicular Lymphoma	Norway	Bristol-Myers Squibb Pharma EEIG	14 Jun 2007
Mantle-Cell Lymphoma	European Union	Bristol-Myers Squibb Pharma EEIG	14 Jun 2007
Mantle-Cell Lymphoma	Iceland	Bristol-Myers Squibb Pharma EEIG	14 Jun 2007
Mantle-Cell Lymphoma	Liechtenstein	Bristol-Myers Squibb Pharma EEIG	14 Jun 2007
Mantle-Cell Lymphoma	Norway	Bristol-Myers Squibb Pharma EEIG	14 Jun 2007
Transfusion dependent anaemia	European Union	Bristol-Myers Squibb Pharma EEIG	14 Jun 2007
Transfusion dependent anaemia	Iceland	Bristol-Myers Squibb Pharma EEIG	14 Jun 2007
Transfusion dependent anaemia	Liechtenstein	Bristol-Myers Squibb Pharma EEIG	14 Jun 2007
Transfusion dependent anaemia	Norway	Bristol-Myers Squibb Pharma EEIG	14 Jun 2007
Multiple Myeloma	United States	Bristol Myers Squibb Co.	29 Jun 2006

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
T-cell/histiocyte rich large B-cell lymphoma	Phase 3	United States	Incyte Corp.	11 May 2021
T-cell/histiocyte rich large B-cell lymphoma	Phase 3	Japan	Incyte Corp.	11 May 2021
T-cell/histiocyte rich large B-cell lymphoma	Phase 3	Argentina	Incyte Corp.	11 May 2021
T-cell/histiocyte rich large B-cell lymphoma	Phase 3	Australia	Incyte Corp.	11 May 2021
T-cell/histiocyte rich large B-cell lymphoma	Phase 3	Austria	Incyte Corp.	11 May 2021
T-cell/histiocyte rich large B-cell lymphoma	Phase 3	Canada	Incyte Corp.	11 May 2021
T-cell/histiocyte rich large B-cell lymphoma	Phase 3	Colombia	Incyte Corp.	11 May 2021
T-cell/histiocyte rich large B-cell lymphoma	Phase 3	Czechia	Incyte Corp.	11 May 2021
T-cell/histiocyte rich large B-cell lymphoma	Phase 3	France	Incyte Corp.	11 May 2021
T-cell/histiocyte rich large B-cell lymphoma	Phase 3	Germany	Incyte Corp.	11 May 2021

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00403169 (CTgov)	Phase 2	Advanced Renal Cell Carcinoma	28	Lenalidomide	maxoiprgey = hgkxwrxlto pqebkwkjle (ycuxmfacdp, mivfswbtgx - jvabdzindn) View more	-	02 Jul 2026
NCT02516423 (CTgov)	Phase 3	Plasmacytoma	11	Lenalidomide+ixazomib+zoledronic acid+dexamethasone (Ixazomib + Lenalidomide + Dexamethasone + Zoledronic Acid)	pgwgfqaqom = nczptdbxul qhbssqssps (qjwbzczmwy, rpsrenaatd - aeckvurrnn) View more	-	30 Jun 2026
NCT02516423 (CTgov)	Phase 3	Plasmacytoma	11	zoledronic acid (Zoledronic Acid)	pgwgfqaqom = tosdpdcblr qhbssqssps (qjwbzczmwy, issfffpych - eayykpstcn) View more	-	30 Jun 2026
EULAR2026	Not Applicable	-	27	Lenalidomide 5-10 mg/day	dlgyvhlkvq(qoqewqxqre) = nsllelfurr ejhyxtwwja (dzyzywfstr ) View more	Positive	11 Jun 2026
NCT04436107 (BGB-3111-110, Pubmed \| Blood Adv)	Phase 1	Diffuse large B-cell lymphoma recurrent	66	LenalidomideZanubrutinib 160 mg twice daily + LenalidomideZanubrutinib 160 mg twice daily	hrueulvgpj(hmimvwwspu) = jchrbbyhcw enkzqamfzo (npgpiqwwga ) View more	Positive	09 Jun 2026
ASCO2026	Not Applicable	-	3,328	Lenalidomide	dxlmvhcykb(wzjargbhga) = noqnuskfvd tuskvawozf (bnrmzevemr ) View more	Positive	29 May 2026
BelaDRd (ASCO2026)	Phase 1/2	Multiple Myeloma First line	36	Belantamab mafodotin+daratumumab+lenalidomide+dexamethasone	aoevidazxb(hrcyittfzz) = nxjvfetiup kjokcefqfs (uvjmdzzfgp ) View more	Positive	29 May 2026
LEN-EOS (ASCO2026)	Not Applicable	Multiple Myeloma	127	Bortezomib+Lenalidomide+Dexamethasone (Lenalidomide-induced eosinophilia)	vgtgghcupm(ogexzueagr) = tshhiixnza yeayceijpf (elpvojxcpi ) View more	Positive	29 May 2026
LEN-EOS (ASCO2026)	Not Applicable	Multiple Myeloma	127	Bortezomib+Lenalidomide+Dexamethasone (No Lenalidomide-induced eosinophilia)	vgtgghcupm(ogexzueagr) = cubitgrzlo yeayceijpf (elpvojxcpi ) View more	Positive	29 May 2026
NCT03290950 (CTgov)	Phase 2	Multiple Myeloma \| Plasma Cell Leukemia	69	Lenalidomide+Carfilzomib+Daratumumab+dexamethasone (Cohort 1)	qsovndyhzn = wwqxmvxqlx iwmycvkegf (xxgbbrkgkd, rmhjkcemjc - dtrogpbawz) View more	-	29 May 2026
NCT03290950 (CTgov)	Phase 2	Multiple Myeloma \| Plasma Cell Leukemia	69	Lenalidomide+Carfilzomib+Daratumumab+dexamethasone (Cohort 2)	qsovndyhzn = rjnfvljios iwmycvkegf (xxgbbrkgkd, gxuaxpkobf - umvksshoig) View more	-	29 May 2026
ChiCTR2500103716 (EHA2026)	Phase 2	Acute Myeloid Leukemia \| Myelodysplastic Syndromes First line	15	Venetoclax + Azacitidine + Lenalidomide (AVL)	kliwuyihcl(idfcxyxuue) = vnpywgpixw hniegiqreo (ljkybunzao ) View more	Positive	12 May 2026
ChiCTR2500103716 (EHA2026)	Phase 2		15	Venetoclax + Azacitidine + Lenalidomide (AVL) (TP53 gene mutations)	kliwuyihcl(idfcxyxuue) = emercjuble hniegiqreo (ljkybunzao )	Positive	12 May 2026
PTL-2022 (EHA2026)	Not Applicable	Testicular Neoplasms	12	R-mNHL-BFM-90 regimen with ibrutinib and lenalidomide followed by autologous HSCT	iihsmhcank(ugjuhaauce) = tffkvkyiuo xlcdiwdixt (lewxepfjgs )	Positive	12 May 2026

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis